A share price of Acadia Pharmaceuticals Inc [ACAD] is currently trading at $22.99, up 4.41%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ACAD shares have gain 9.79% over the last week, with a monthly amount glided 9.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on October 21, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $33. Previously, Deutsche Bank upgraded its rating to Buy on May 21, 2025, and kept the price target unchanged to $35. On February 11, 2025, Deutsche Bank initiated with a Hold rating and assigned a price target of $22 on the stock. Guggenheim downgraded its rating to a Neutral and decreased its price target to $20 on January 03, 2025. Morgan Stanley downgraded its rating to Equal-Weight for this stock on August 07, 2024, and downed its price target to $20. In a note dated June 27, 2024, BMO Capital Markets initiated an Outperform rating and provided a target price of $31 on this stock.
Acadia Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $13.40 and $26.65. Currently, Wall Street analysts expect the stock to reach $29.33 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $22.99 at the most recent close of the market. An investor can expect a potential return of 27.58% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
Trailing Twelve Months sales for Acadia Pharmaceuticals Inc [NASDAQ:ACAD] were 1.02B which represents 9.34% growth. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.31 and Total Capital is 0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.30 points at the first support level, and at 21.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.35, and for the 2nd resistance point, it is at 23.70.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Acadia Pharmaceuticals Inc [NASDAQ:ACAD] is 2.91. Further, the Quick Ratio stands at 2.83, while the Cash Ratio is 0.77. Considering the valuation of this stock, the price to sales ratio is 3.81, the price to book ratio is 4.71 and price to earnings (TTM) ratio is 17.28.
Transactions by insiders
Recent insider trading involved Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, that happened on Sep 15 ’25 when 3498.0 shares were sold. Director, GAROFALO ELIZABETH A. completed a deal on Sep 02 ’25 to sell 1600.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold 22000.0 shares on Aug 18 ’25.
